AA
CTMX icon

AlphaMark Advisors’s CytomX Therapeutics CTMX Stock Holding History

AlphaMark Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,183
Closed -$36K – 728
2023
Q4 		$36K Buy
23,183
+12,635
+120% +$16.6K 0.01% 373
2023
Q3 		$14K Hold
10,548
– – 0.01% 467
2023
Q2 		$18K Buy
10,548
+6,015
+133% +$9.99K 0.01% 324
2023
Q1 		$7K Buy
+4,533
New +$10.2K ﹤0.01% 456
2022
Q4 		– Sell
-20,000
Closed -$29K – 618
2022
Q3 		$29K Hold
20,000
– – 0.01% 262
2022
Q2 		$37K Buy
20,000
+17,000
+567% +$32.5K 0.02% 242
2022
Q1 		$8K Buy
+3,000
New +$11.5K ﹤0.01% 426
2020
Q3 		– Sell
-1,390
Closed -$12K – 538
2020
Q2 		$12K Hold
1,390
– – 0.01% 335
2020
Q1 		$11K Buy
1,390
+413
+42% +$2.88K 0.01% 291
2019
Q4 		$8K Buy
977
+440
+82% +$2.97K ﹤0.01% 355
2019
Q3 		$4K Buy
537
+175
+48% +$1.73K ﹤0.01% 408
2019
Q2 		$4K Hold
362
– – ﹤0.01% 432
2019
Q1 		$4K Hold
362
– – ﹤0.01% 418
2018
Q4 		$5K Buy
+362
New +$5.37K ﹤0.01% 371

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AlphaMark Advisors's CTMX Position: Q1 2024 in Review

AlphaMark Advisors sold out of CytomX Therapeutics (CTMX) in Q1 2024, closing a stake of 23,183 shares — an estimated $36K sold.

AlphaMark Advisors first reported a position in CTMX in Q4 2018 and held it in 14 quarters. The position peaked at $37K in Q2 2022. 88 funds tracked by Wall St. Rank hold CTMX as of Q1 2024.

  • AlphaMark Advisors reported no remaining CytomX Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 23,183 CytomX Therapeutics shares in Q1 2024, an estimated $36K.
  • AlphaMark Advisors first reported a position in CytomX Therapeutics in Q4 2018 and held it in 14 quarters.
  • AlphaMark Advisors's CytomX Therapeutics position peaked at $37K in Q2 2022.
  • 88 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2024.

Based on AlphaMark Advisors's 13F filing for Q1 2024, filed 18 Apr 2024.